A presentation summarising the clinical benefits of the treat to target approach in inflammatory bowel disease, particularly reflecting on the changes in adverse endpoint rate reported in the CALM study and the REACT1 trial. Following this, there is an illuminating pharmacoeconomic analysis of the CALM study.
Speaker
- Geert D’Haens (Academic Medical Centre, Amsterdam, The Netherlands.)
This video was funded by AbbVie.
